An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study

An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study

Introduction: Patients with stage III NSCLC represent a very heterogenous group that requires different treatment strategies, especially in patients with N2 (2 nearby lymph nodes having cancer)-positive NSCLC and unresectable EGFR-mutant NSCLC. This real-world study may provide more insights into tr...

Full description

Bibliographic Details
Main Authors:	Po-Lan Su, MD, Gee-Chen Chang, MD, Shih-Hsin Hsiao, MD, Te-Chun Hsia, MD, Meng-Chih Lin, MD, Min-Hsi Lin, MD, Jin-Yuan Shih, MD, Cheng-Ta Yang, MD, Sheng-Hsiung Yang, MD, Yuh-Min Chen, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	JTO Clinical and Research Reports
Subjects:	Stage III non-small cell lung cancer N2-positive disease Epidermal growth factor receptor mutation Chemoradiotherapy Tyrosine kinase inhibitors
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364322000169

Similar Items

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
by: Sheng‐Yuan Wang, et al.
Published: (2022-01-01)

Targeting MET in NSCLC: An Ever-Expanding Territory
by: Ying Han, MD, et al.
Published: (2024-02-01)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
by: Narek Shaverdian, MD, et al.
Published: (2021-07-01)

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
by: Kumar Prabhash, et al.
Published: (2023-03-01)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
by: Wei‐Chun Chen, et al.
Published: (2024-04-01)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC—RELANCE/LACOG 0118
by: Vladmir C. Cordeiro de Lima, MD, PhD, et al.
Published: (2024-03-01)

The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
by: Lye-Yeng Wong, MD, et al.
Published: (2024-03-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
by: Gokhan Yaprak, et al.
Published: (2019-06-01)

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort
by: Tu Van Dao, et al.
Published: (2022-05-01)

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report
by: Shelby Edmondson, BA, et al.
Published: (2022-08-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Osimertinib-associated erythema dyschromicum perstans–like eruption: A case series
by: Christina S. Oh, BA, et al.
Published: (2023-05-01)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
by: David E. Gerber, MD, et al.
Published: (2022-03-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
by: Giannis Mountzios, MD, PhD, et al.
Published: (2023-01-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
by: Ryo Ariyasu, MD, et al.
Published: (2023-06-01)

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective
by: Yuyan Zheng, MD, et al.
Published: (2022-03-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2023-05-01)

The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
by: Merle I. Ronden, MD, et al.
Published: (2021-07-01)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
by: Liesbeth M. Hondelink, MD, et al.
Published: (2021-12-01)

Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
by: Areo G. Saffarzadeh, MD, MS, et al.
Published: (2021-08-01)

Adult-onset verrucous epidermal nevus overlying an implanted cardioverter-defibrillator
by: Mohammed A. AlFada, MD, MBA, et al.
Published: (2023-04-01)

Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC
by: Daegan Sit, MD, et al.
Published: (2022-08-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
by: Scott N. Gettinger, MD, et al.
Published: (2022-09-01)

Epidermal inclusion cyst in male breast: how to differentiate from other male breast lesions
by: Murat Ak, MD, et al.
Published: (2022-10-01)

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
by: Sik-Kwan Chan, PhD, et al.
Published: (2022-05-01)

Epidermal inclusion cyst of the axilla with calcifications
by: Eman Abu-Mandeel, MD, et al.
Published: (2023-03-01)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Gwo-Fuang Ho, et al.
Published: (2019-09-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
by: Tejas Patil, MD, et al.
Published: (2024-02-01)

Beyond guesswork: how accurate are surgeons at determining the degree of glenoid bone loss in instability surgery?
by: Caleb A. LaVigne, MD, et al.
Published: (2024-03-01)

Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
by: Jiyun Lee, et al.
Published: (2024-04-01)